pubrio
Shionogi Pharma (formerly Sciele Pharma)

Shionogi Pharma (formerly Sciele Pharma)

United States · Pharmaceuticals

Pharmaceuticals

Since 1878, we have been committed to developing new treatments to improve patients' lives worldwide. We are helping to address global health challenges such as antimicrobial resistance and COVID-19. Since the 1950s, we have discovered and introduced several novel antibiotics, as well as innovative medications for HIV and influenza. Today, we are developing an investigational oral antiviral for COVID-19 and advancing clinical programs in Fragile X syndrome, acute ischemic stroke as well metabolic disorders and oncology. Our team is driven to impact patient lives. Our partnerships with industry, government agencies, biotech companies and academia help to advance science with the urgency that today's health challenges demand. Through a combination of in-house discovery and strategic partnerships, we continue to deliver firsts for patients in the U.S. and worldwide.

Company Insights
Company Overview

2001

Founded

Pharmaceuticals

Industry

United States

Location

1,187,976

Ranking

5,000 employees

Size

Similar Companies

Get full access to view complete information

Frequently Asked Questions Regarding Shionogi Pharma (formerly Sciele Pharma)

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​